{{noteTA
|T = zh-cn:诺瓦瓦克斯2019冠状病毒病疫苗; zh-hk:諾瓦瓦克斯2019冠狀病毒病疫苗; zh-mo:諾瓦瓦克斯2019冠狀病毒病疫苗; zh-tw:諾瓦瓦克斯嚴重特殊傳染性肺炎疫苗; zh-sg:诺瓦瓦克斯2019冠状病毒疾病疫苗; zh-my:诺瓦瓦克斯2019冠状病毒病疫苗;
|G1=ME
|G2=TO
}}
{{Infobox drug
| Verifiedfields     = 
| verifiedrevid      = 
| drug_name          = 
| INN                = 
| type               = 疫苗
| image              = 
| alt                = 
| caption            = 
| target             = [[嚴重急性呼吸綜合症冠狀病毒2型|SARS-CoV-2]]
| vaccine_type 	= [[蛋白質亞基|蛋白質亞基]]疫苗
<!-- Clinical data -->
| pronounce          = 
| tradename          = Covovax<ref name="covovax"/>,Nuvaxovid
| Drugs.com          = 
| MedlinePlus        = 
| licence_EU         = 
| licence_US         = 
| pregnancy_AU       = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_category = 
| legal_AU           = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment   = 
| legal_BR           = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment   = 
| legal_CA           = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK           = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US           = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_UN           = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_NZ           = <!--Class A, B, C -->
| legal_status       = 
| routes_of_administration = [[肌肉注射|肌肉注射]]
<!-- Identifiers -->
| CAS_number         = 
| ATCvet             = 
| ATC_prefix         = None <!-- scheduled to be J07BX03 in 2022 -->
| ATC_suffix         = 
| PubChem            = 
| DrugBank           = DB15810
| synonyms          = NVX-CoV2373
}}
'''诺瓦瓦克斯2019冠状病毒疾病疫苗'''（[[商品名|商品名]]：Covovax<ref name="covovax">{{cite news|title=Covovax trials begin in India, launch hopefully in September: Adar Poonawalla|url=https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/covovax-trials-begin-in-india-serum-institute-novavax-adar-poonawalla-1784381-2021-03-27|access-date=2021-03-28|publisher=[[India_Today|India Today]]|date=2021-03-27|archive-date=2021-05-14|archive-url=https://web.archive.org/web/20210514153621/https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/covovax-trials-begin-in-india-serum-institute-novavax-adar-poonawalla-1784381-2021-03-27|dead-url=no}}</ref><ref>{{cite news|title=Hope to launch Covovax by September, says Serum Institute CEO|url=https://www.livemint.com/companies/news/hope-to-launch-covovax-by-september-says-serum-institute-ceo-11616834205232.html|access-date=2021-03-28|work=mint|date=2021-03-27|archive-date=2021-05-13|archive-url=https://web.archive.org/web/20210513082056/https://www.livemint.com/companies/news/hope-to-launch-covovax-by-september-says-serum-institute-ceo-11616834205232.html|dead-url=no}}</ref><ref>{{Cite journal|title=Novavax’s fridge-friendly vaccine impresses|url=http://www.nature.com/articles/s41587-021-00991-8|date=2021-07|journal=Nature Biotechnology|issue=7|doi=10.1038/s41587-021-00991-8|volume=39|pages=784–784|language=en|issn=1087-0156|access-date=2021-08-30|archive-date=2021-07-27|archive-url=https://web.archive.org/web/20210727194842/https://www.nature.com/articles/s41587-021-00991-8|dead-url=no}}</ref>,Nuvaxovid，代號： '''NVX-CoV2373'''） ，為一款已投入應用的[[2019冠狀病毒病疫苗|2019冠狀病毒病疫苗]]，由美國[[諾瓦瓦克斯醫藥|諾瓦瓦克斯醫藥]]（Novavax）及{{link-en|流行病預防創新聯盟|Coalition for Epidemic Preparedness Innovations}}（CEPI）合作研製。此疫苗與絕大多數同類疫苗，均需接種兩次<ref name="doi 10.1126/science.abg8101">{{Cite journal|title=Novavax vaccine delivers 89% efficacy against COVID-19 in U.K.—but is less potent in South Africa|url=https://www.sciencemag.org/news/2021/01/novavax-vaccine-delivers-89-efficacy-against-covid-19-uk-less-potent-south-africa|last=Wadman|first=Meredith|date=2021-01-28|journal=Science|doi=10.1126/science.abg8101|issn=0036-8075|access-date=2021-08-30|archive-date=2021-05-25|archive-url=https://web.archive.org/web/20210525001826/https://www.sciencemag.org/news/2021/01/novavax-vaccine-delivers-89-efficacy-against-covid-19-uk-less-potent-south-africa|dead-url=no}}</ref>，但可於較高的溫度下（即 {{convert|2|to|8|C|F}}）冷藏<!-- (36°F to 46°F) --><ref name="BBC 20210108" />。[[世衛組織|世衛組織]]於2021年12月17日及21日先後向[[印度血清研究所|印度血清研究所]]及諾瓦瓦克斯原廠發出該種疫苗的緊急使用授權<ref name="WHO諾瓦瓦克斯疫苗">{{cite news |title=世卫组织将第十种新冠疫苗列入紧急使用清单 |url=https://news.un.org/zh/story/2021/12/1096432 |accessdate=2022-01-01 |work=聯合國新聞 |date=2021-12-21}}</ref>。

== 技術 ==
諾瓦瓦克斯COVID-19疫苗採用[[蛋白質亞基|蛋白質亞基]]<ref name=":1">{{cite journal | vauthors = Wadman M | title = The long shot | journal = Science | volume = 370 | issue = 6517 | pages = 649–653 | date = November 2020 | pmid = 33154120 | doi = 10.1126/science.370.6517.649 | bibcode = 2020Sci...370..649W | doi-access = free }}</ref><ref name=":2">{{cite journal|vauthors=Wadman M|date=2020-12-28|title=Novavax launches pivotal U.S. trial of dark horse COVID-19 vaccine after manufacturing delays|url=https://www.sciencemag.org/news/2020/12/novavax-launches-pivotal-us-trial-dark-horse-covid-19-vaccine-after-manufacturing|journal=Science|doi=10.1126/science.abg3441|access-date=2021-04-05|archive-date=2021-05-13|archive-url=https://web.archive.org/web/20210513165035/https://www.sciencemag.org/news/2020/12/novavax-launches-pivotal-us-trial-dark-horse-covid-19-vaccine-after-manufacturing|dead-url=no}}</ref><ref name="Novavax">{{cite news |vauthors=Parekh N |title=Novavax: A SARS-CoV-2 Protein Factory to Beat COVID-19. |url=https://fancycomma.com/2020/07/24/novavax-protein-subunit-covid-19-vaccine/ |access-date=2020-07-24 |date=2020-07-24 |archive-date=2020-11-22 |archive-url=https://web.archive.org/web/20201122040118/https://fancycomma.com/2020/07/24/novavax-protein-subunit-covid-19-vaccine/ |dead-url=no }}</ref>及重組病毒[[糖蛋白|糖蛋白]][[納米顆粒|納米顆粒]]技術<ref>{{Cite journal|title=COVID-19 Vaccine Frontrunners and Their Nanotechnology Design|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553041/|last=Chung|first=Young Hun|last2=Beiss|first2=Veronique|date=2020-10-09|journal=ACS Nano|doi=10.1021/acsnano.0c07197|issn=1936-0851|pmc=7553041|pmid=33034449|last3=Fiering|first3=Steven N.|last4=Steinmetz|first4=Nicole F.|access-date=2021-08-30|archive-date=2021-10-19|archive-url=https://web.archive.org/web/20211019082803/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553041/|dead-url=no}}</ref><ref>{{cite journal | vauthors = Medhi R, Srinoi P, Ngo N, Tran HV, Lee TR |date=2020-09-25 |title=Nanoparticle-Based Strategies to Combat COVID-19 |journal=ACS Applied Nano Materials |volume=3 |issue=9 |pages=8557–8580 |doi=10.1021/acsanm.0c01978 |pmc=7482545 }}</ref><ref name=":3">{{cite web|title=Urgent global health needs addressed by Novavax|url=https://www.novavax.com/our-unique-technology|access-date=2021-01-30|website=Novavax|archive-url=https://web.archive.org/web/20210512090816/https://www.novavax.com/our-unique-technology|archive-date=2021-05-12|dead-url=no}}</ref>，並分為兩個階段生產：在第一階段，經改造、含有製造[[SARS-CoV-2|SARS-CoV-2]]外殼刺突蛋白基因的[[棒狀病毒科|棒狀病毒]]，會感染用作培殖的[[Sf9細胞|Sf9細胞]]，以產生刺突蛋白。而在第二階段，上階段製造的蛋白會被收集，並注入至直徑為50納米的固體脂質[[納米顆粒|納米粒]]，每粒含有14枚SARS-CoV-2的刺突蛋白<ref name=":1" /><ref name=":2" /><ref name=":3" />。

除了上述的蛋白顆粒外，此疫苗亦含有以[[皂苷|皂苷]]為基礎的[[免疫佐劑|免疫佐劑]]<ref name=":1" /><ref name=":2" /><ref name=":3" />。

== 研發歷史 ==
2020年1月，諾瓦瓦克斯醫藥宣佈將會研發COVID-19疫苗，並給予代號為NVX-CoV2373<ref name="gilgore">{{cite news |vauthors=Gilgore S |title=Novavax is working to advance a potential coronavirus vaccine. So are competitors. |url=https://www.bizjournals.com/washington/news/2020/02/26/novavax-is-moving-forward-with-a.html |work=Washington Business Journal |access-date=2020-03-06 |date=2020-02-26 |archive-date=2020-03-16 |archive-url=https://web.archive.org/web/20200316041227/https://www.bizjournals.com/washington/news/2020/02/26/novavax-is-moving-forward-with-a.html |dead-url=no }}</ref>。其時，市場上尚有十數家藥廠研發同類疫苗<ref name="milken">{{cite web |title=COVID-19 vaccine tracker (click on 'Vaccines' tab) |url=https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/htmlview?pru=AAABchldaXU*ZWdU7a75RG6u_cw8QpEBhw# |publisher=Milken Institute |access-date=2020-05-12 |date=2020-05-11 |lay-url=https://milkeninstitute.org/covid-19-tracker |archive-date=2020-06-06 |archive-url=https://web.archive.org/web/20200606220149/https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/htmlview?pru=AAABchldaXU*ZWdU7a75RG6u_cw8QpEBhw |dead-url=no }}</ref>。

2020年3月，美國生物科技公司Emergent BioSolutions 獲諾瓦瓦克斯醫藥委託，以進行此疫苗的臨床前研究及早期人體試驗<ref>{{cite news|url=https://www.bizjournals.com/washington/news/2020/03/10/novavax-s-coronavirus-vaccine-program-is-getting.html|title=Novavax's coronavirus vaccine program is getting some help from Emergent BioSolutions|vauthors=Gilgore S|date=2020-03-10|work=Washington Business Journal|access-date=2020-03-10|archive-date=2020-04-09|archive-url=https://web.archive.org/web/20200409200636/https://www.bizjournals.com/washington/news/2020/03/10/novavax-s-coronavirus-vaccine-program-is-getting.html|dead-url=no}}</ref>。 

2020年5月，NVX-CoV2373疫苗於澳洲開展首次人體安全性測試<ref name=fp>{{cite news|title=Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine work|vauthors=Sagonowsky E|url=https://www.fiercepharma.com/vaccines/novavax-scores-cepi-s-largest-award-up-to-384m-to-support-covid-19-vaccine-work|work=FiercePharma|date=2020-05-11|access-date=2020-05-12|archive-date=2020-05-16|archive-url=https://web.archive.org/web/20200516215744/https://www.fiercepharma.com/vaccines/novavax-scores-cepi-s-largest-award-up-to-384m-to-support-covid-19-vaccine-work|dead-url=no}}</ref><ref>{{cite web|title=Novavax starts clinical trial of its coronavirus vaccine candidate|url=https://www.cnbc.com/2020/05/25/novavax-starts-phase-1-clinical-trial-of-coronavirus-vaccine-candidate.html|date=2020-05-25|publisher=CNBC|access-date=2020-05-26|archive-date=2020-05-26|archive-url=https://web.archive.org/web/20200526013622/https://www.cnbc.com/2020/05/25/novavax-starts-phase-1-clinical-trial-of-coronavirus-vaccine-candidate.html|dead-url=no}}</ref>。

2020年7月，諾瓦瓦克斯醫藥宣佈美國聯邦政府將透過「[[曲速行動|曲速行動]]」，向此疫苗開發項目有條件批出160億美元的津貼<ref name=":0">{{cite news|vauthors=Steenhuysen J|date=2020-07-07|title=U.S. government awards Novavax $1.6 billion for coronavirus vaccine|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-novavax-idUSKBN248182|access-date=2020-09-15|archive-date=2020-09-14|archive-url=https://web.archive.org/web/20200914213046/https://www.reuters.com/article/us-health-coronavirus-novavax-idUSKBN248182|dead-url=no}}</ref>。

2020年9月尾至12月，NVX-CoV2373疫苗的第三期臨床測試，分別於英國<ref>{{cite news|vauthors=Thomas K, Zimmer C|date=2020-09-24|title=Novavax Enters Final Stage of Coronavirus Vaccine Trials|work=The New York Times|url=https://www.nytimes.com/2020/09/24/health/covid-19-vaccine-novavax.html|access-date=2020-09-28|issn=0362-4331|archive-date=2020-09-28|archive-url=https://web.archive.org/web/20200928031642/https://www.nytimes.com/2020/09/24/health/covid-19-vaccine-novavax.html|dead-url=no}}</ref>、美國及墨西哥進行，當中在美墨兩國的測試代號為「PREVENT-19」（NCT04611802）<ref>{{ClinicalTrialsGov|NCT04611802|A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2}}</ref>{{Full citation needed|date=February 2021}}<ref>{{cite web | title=Phase 3 trial of Novavax investigational COVID-19 vaccine opens | website=National Institutes of Health (NIH) | date=2020-12-28 | url=https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens | access-date=2020-12-28 | archive-date=2021-01-19 | archive-url=https://web.archive.org/web/20210119074047/https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens | dead-url=no }}</ref>。

2020年9月2日，NVX-CoV2373疫苗的第一、二期臨床測試數據及結果被發表於《[[新英格兰医学杂志|新英格蘭醫學期刊]]》<ref>{{Cite journal|title=Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine|url=https://doi.org/10.1056/NEJMoa2026920|last=Keech|first=Cheryl|last2=Albert|first2=Gary|date=2020-12-10|journal=New England Journal of Medicine|issue=24|doi=10.1056/NEJMoa2026920|volume=383|pages=2320–2332|issn=0028-4793|pmc=PMC7494251|pmid=32877576|last3=Cho|first3=Iksung|last4=Robertson|first4=Andreana|last5=Reed|first5=Patricia|last6=Neal|first6=Susan|last7=Plested|first7=Joyce S.|last8=Zhu|first8=Mingzhu|last9=Cloney-Clark|first9=Shane}}</ref>。

2021年1月28日，NVX-CoV2373疫苗於英國的第三期臨床測試結果公佈，指出其預防有效率達89%<ref>{{cite news|vauthors=Lovelace B|date=2020-01-28|title=Novavax says Covid vaccine is more than 89% effective|work=CNBC|url=https://www.cnbc.com/2021/01/28/covid-vaccine-novavax-says-covid-vaccine-is-more-than-89percent-effective.html|accessdate=2021-04-05|archive-date=2021-01-30|archive-url=https://web.archive.org/web/20210130124318/https://www.cnbc.com/2021/01/28/covid-vaccine-novavax-says-covid-vaccine-is-more-than-89percent-effective.html|dead-url=no}}</ref><ref name="BBC 20210108">{{cite news|date=2021-01-28|title=New Covid vaccine shows 89% efficacy in UK trials|work=BBC News|url=https://www.bbc.com/news/uk-55850352|access-date=2021-01-28|archive-date=2021-04-29|archive-url=https://web.archive.org/web/20210429173739/https://www.bbc.com/news/uk-55850352|dead-url=no}}</ref>，但中期測試結果指出此疫苗針對[[严重急性呼吸综合征冠状病毒2变种|南非變種病毒株]]，僅有約50-60%的有效率<ref name="doi 10.1126/science.abg8101" /><ref>{{cite web | vauthors=Facher L, Joseph A | title=Novavax says its Covid-19 vaccine is 90% effective in late-stage trial | website=[[Stat_(website)|Stat]] | date=2021-01-28 | url=https://www.statnews.com/2021/01/28/novavax-says-its-covid-19-vaccine-is-90-effective-but-far-less-so-against-one-variant/ | access-date=2021-01-29 | archive-date=2021-01-29 | archive-url=https://web.archive.org/web/20210129235353/https://www.statnews.com/2021/01/28/novavax-says-its-covid-19-vaccine-is-90-effective-but-far-less-so-against-one-variant/ | dead-url=no }}</ref>。

2021年3月12日，諾瓦瓦克斯醫藥公佈此疫苗更詳細測試結果，其預防有效率達到96.4%，而針對英國及南非變種病毒株則為86%及55%；另外，諾瓦瓦克斯声称此疫苗預防重症的有效率為100%<ref name=":4">{{Cite news|last=O’Donnell|first=Carl|last2=Nadeem|first2=Dania|date=2021-03-11|title=Novavax vaccine 96% effective against original coronavirus, 86% vs British variant in UK trial|work=Reuters|url=https://www.reuters.com/article/uk-health-coronavirus-vaccines-novavax-idUSKBN2B32ZI|access-date=2021-03-23|archive-date=2021-05-04|archive-url=https://web.archive.org/web/20210504051743/https://www.reuters.com/article/uk-health-coronavirus-vaccines-novavax-idUSKBN2B32ZI|dead-url=no}}</ref><ref>{{Cite web|title=诺瓦瓦克斯声称 疫苗经试验100%能预防重症|url=https://www.swissinfo.ch/chi/%E8%AF%BA%E7%93%A6%E7%93%A6%E5%85%8B%E6%96%AF%E5%A3%B0%E7%A7%B0-%E7%96%AB%E8%8B%97%E7%BB%8F%E8%AF%95%E9%AA%8C100-%E8%83%BD%E9%A2%84%E9%98%B2%E9%87%8D%E7%97%87/46442402|access-date=2021-05-13|work=SWI swissinfo.ch|publisher=[[瑞士资讯|瑞士资讯]]|language=zh|archive-date=2021-05-13|archive-url=https://web.archive.org/web/20210513062856/https://www.swissinfo.ch/chi/%E8%AF%BA%E7%93%A6%E7%93%A6%E5%85%8B%E6%96%AF%E5%A3%B0%E7%A7%B0-%E7%96%AB%E8%8B%97%E7%BB%8F%E8%AF%95%E9%AA%8C100-%E8%83%BD%E9%A2%84%E9%98%B2%E9%87%8D%E7%97%87/46442402|dead-url=no}}</ref>。同年6月，諾瓦瓦克斯醫藥又表示經過美國和墨西哥3萬多人的測試，疫苗的整體有效率為90.4%<ref>{{cite news |title=諾瓦瓦克斯公布其研發的新冠疫苗有效率逾九成 |url=https://news.rthk.hk/rthk/ch/component/k2/1595828-20210615.htm |accessdate=2021-06-15 |archive-date=2021-06-16 |archive-url=https://web.archive.org/web/20210616043125/https://news.rthk.hk/rthk/ch/component/k2/1595828-20210615.htm |dead-url=no }}</ref>。

2021年12月17日，[[世界衛生組織|世界衛生組織]]宣布，批准第8款新冠疫苗<ref>[https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued 批准第8款新冠疫苗] {{Wayback|url=https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued |date=20211221213532 }}</ref>，將Covovax疫苗列入緊急使用名單。

2021年12月20日，歐盟委員會接納[[歐洲藥品管理局|歐洲藥品管理局]]建議，批准向18歲或以上人士接種美國藥廠諾瓦瓦克斯（Novavax）研發的新型冠狀病毒肺炎（COVID-19）疫苗Nuvaxovid，為歐盟批准使用的第5款疫苗<ref>{{Cite web|title=新冠肺炎｜歐盟批准使用Novavax疫苗|url=https://www.hk01.com/%E5%8D%B3%E6%99%82%E5%9C%8B%E9%9A%9B/714750/%E6%96%B0%E5%86%A0%E8%82%BA%E7%82%8E-%E6%AD%90%E7%9B%9F%E6%89%B9%E5%87%86%E4%BD%BF%E7%94%A8novavax%E7%96%AB%E8%8B%97|date=2021-12-21|newspaper=香港01|access-date=2021-12-21|archive-date=2021-12-21|archive-url=https://web.archive.org/web/20211221042704/https://www.hk01.com/%E5%8D%B3%E6%99%82%E5%9C%8B%E9%9A%9B/714750/%E6%96%B0%E5%86%A0%E8%82%BA%E7%82%8E-%E6%AD%90%E7%9B%9F%E6%89%B9%E5%87%86%E4%BD%BF%E7%94%A8novavax%E7%96%AB%E8%8B%97|dead-url=no}}</ref><ref>{{Cite web|title=Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted)|url=https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid|date=2021-12-20|website=EMA|access-date=2021-12-22|archive-date=2021-12-23|archive-url=https://web.archive.org/web/20211223093752/https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid|dead-url=no}}</ref>。

== 生產及應用 ==
=== 授權生產 ===
2020年3月，負責此疫苗早期開發的美國生物科技公司Emergent BioSolutions，同時獲授權在該公司設於[[巴爾的摩|巴爾的摩]]的廠房代為生產疫苗<ref>{{cite web|vauthors=McCartney R|title=Maryland plays an outsized role in worldwide hunt for a coronavirus vaccine|url=https://www.washingtonpost.com/local/maryland-plays-an-outsized-role-in-worldwide-hunt-for-a-coronavirus-vaccine/2020/05/03/3b6f2cb8-8bd5-11ea-8ac1-bfb250876b7a_story.html|website=Washington Post|dead-url=no|archive-url=https://web.archive.org/web/20200507230732/https://www.washingtonpost.com/local/maryland-plays-an-outsized-role-in-worldwide-hunt-for-a-coronavirus-vaccine/2020/05/03/3b6f2cb8-8bd5-11ea-8ac1-bfb250876b7a_story.html|archive-date=2020-05-07|access-date=2020-05-08}}</ref>。隨後，[[富士胶片|富士菲林]]旗下在英國[[比林漢姆|比林漢姆]]的Diosynth藥廠（下稱「富士廠房」）<ref name=guardian-20210128>{{cite news |url=https://www.theguardian.com/society/2021/jan/28/novavax-covid-vaccine-shown-to-be-nearly-90-effective-in-uk-trial |title=Novavax Covid vaccine shown to be nearly 90% effective in UK trial |vauthors=Boseley S, Davis N |newspaper=The Guardian |date=2021-01-28 |access-date=2021-01-29 |archive-date=2021-04-12 |archive-url=https://web.archive.org/web/20210412163928/https://www.theguardian.com/society/2021/jan/28/novavax-covid-vaccine-shown-to-be-nearly-90-effective-in-uk-trial |dead-url=no }}</ref>、[[印度血清研究所|印度血清研究所]]亦獲授權生產此疫苗<ref>{{cite news |title=Novavax signs COVID-19 vaccine supply deal with India's Serum Institute |url=https://www.reuters.com/article/us-health-coronavirus-novavax/novavax-signs-covid-19-vaccine-supply-deal-with-indias-serum-institute-idINKCN25139A |work=Reuters |date=2020-08-05 |accessdate=2021-04-05 |archive-date=2021-03-19 |archive-url=https://web.archive.org/web/20210319014912/https://www.reuters.com/article/us-health-coronavirus-novavax/novavax-signs-covid-19-vaccine-supply-deal-with-indias-serum-institute-idINKCN25139A |dead-url=no }}</ref>；當中，富士廠房將負責生產英國政府訂購的6,000萬劑疫苗<ref name=teesidelive-20200814>{{cite news |url=https://www.gazettelive.co.uk/news/teesside-news/60m-doses-new-covid-19-18767512 |title=60m doses of new covid-19 vaccine could be made in Billingham – and be ready for mid-2021 |vauthors=Brown M |website=TeesideLive |publisher=Reach |date=2020-08-14 |access-date=2021-01-29 |archive-date=2021-02-07 |archive-url=https://web.archive.org/web/20210207060752/https://www.gazettelive.co.uk/news/teesside-news/60m-doses-new-covid-19-18767512 |dead-url=no }}</ref>，而後者代工生產的疫苗主要出口至發展中國家。

除上述的藥廠外，西班牙藥廠Zendal<ref>{{cite web | title = Spain, again chosen to produce the vaccine to combat COVID-19 | date = 2020-09-18 | url = https://www.thisistherealspain.com/en/latest-news/spain-again-chosen-to-produce-the-vaccine-to-combat-covid-19/?fbclid=IwAR2x7HPGpchz5Ib1fpcMiltQQ3fl3bcNKibpTUOJbBDxiDFZ98nougKtypA | work = This is the Real Spain | access-date = 2021-04-05 | archive-date = 2021-03-19 | archive-url = https://web.archive.org/web/20210319015957/https://www.thisistherealspain.com/en/latest-news/spain-again-chosen-to-produce-the-vaccine-to-combat-covid-19/?fbclid=IwAR2x7HPGpchz5Ib1fpcMiltQQ3fl3bcNKibpTUOJbBDxiDFZ98nougKtypA | dead-url = no }}</ref>及波蘭Mabion生物科技公司，亦擬承接代工生產NVX-CoV2373疫苗的工作<ref>{{cite web | title = Novavax Deal With Mabion Boosts Poland’s Nascent Biotech Scene | date = 2021-03-25 | url = https://www.bloomberg.com/news/articles/2021-03-03/novavax-deal-with-mabion-boosts-poland-s-nascent-biotech-scene | work = Bloomberg | access-date = 2021-04-05 | archive-date = 2021-03-09 | archive-url = https://web.archive.org/web/20210309181639/https://www.bloomberg.com/news/articles/2021-03-03/novavax-deal-with-mabion-boosts-poland-s-nascent-biotech-scene | dead-url = no }}</ref>。

2021年4月，韓國決定購買4000萬劑諾瓦瓦克斯疫苗，疫苗將通過技術轉讓由韓國[[SK集团|SK生物技術公司]]生產。4月27日，韓國總統[[文在寅|文在寅]]在[[青瓦台|青瓦台]]會見諾瓦瓦克斯行政總裁斯坦利·埃爾克，對諾瓦瓦克斯迅速研發疫苗，並通過技術合作在韓國生產疫苗表達感謝<ref name="文在寅會見諾瓦瓦克斯CEO">{{cite news |title=文在寅接见美国药企诺瓦瓦克斯CEO埃尔克 |url=https://m-cn.yna.co.kr/view/ACK20210427006800881 |accessdate=2021-05-02 |work=韓聯社 |date=2021-04-27 |archive-date=2021-05-02 |archive-url=https://web.archive.org/web/20210502095707/https://m-cn.yna.co.kr/view/ACK20210427006800881 |dead-url=no }}</ref>。

=== 各地使用及引進情況 ===
2020年7月，美國政府通過「曲速行動」，訂購1億劑諾瓦瓦克斯COVID-19疫苗，為此疫苗的首張訂單<ref name=":0"/>。該等疫苗將於[[美國2019冠狀病毒病疫苗接種計劃|美國2019冠狀病毒病疫苗接種計劃]]中應用。

2021年2月2日，加拿大總理[[賈斯汀·杜魯多|杜魯多]]宣佈，該國將會訂購過百萬劑諾瓦瓦克斯COVID-19疫苗，並將於[[蒙特利尔|蒙特婁]]新設的廠房製造<ref>{{cite web | title=Canada signs deal to produce Novavax COVID-19 vaccine at Montreal plant | website=CP24 | date=2021-02-02 | url=https://www.cp24.com/news/canada-signs-deal-to-produce-novavax-covid-19-vaccine-at-montreal-plant-1.5291842 | access-date=2021-02-02 | archive-date=2021-04-28 | archive-url=https://web.archive.org/web/20210428093922/https://www.cp24.com/news/canada-signs-deal-to-produce-novavax-covid-19-vaccine-at-montreal-plant-1.5291842 | dead-url=no }}</ref>。當此疫苗獲得[[加拿大衛生部|加拿大衛生部]]批准後，將成為美國以外首個採用此等疫苗的國家。

2021年3月29日，英國政府宣佈將訂購6,000萬劑諾瓦瓦克斯COVID-19疫苗，以應付[[英國2019冠狀病毒病疫苗接種計劃|英國2019冠狀病毒病疫苗接種計劃]]的需求。該等疫苗將於英國的「富士廠房」生產，並由[[葛蘭素史克|葛蘭素史克]]藥廠負責包裝工序<ref>{{Cite web|title=GSK to support manufacture of Novavax Covid-19 jab at Barnard Castle facility|url=https://www.expressandstar.com/news/uk-news/2021/03/29/gsk-to-support-manufacture-of-novavax-covid-19-jab-at-barnard-castle-facility/|access-date=2021-04-05|date=2021-03-29|publisher=Express & Star|archive-url=https://web.archive.org/web/20210329214343/https://www.expressandstar.com/news/uk-news/2021/03/29/gsk-to-support-manufacture-of-novavax-covid-19-jab-at-barnard-castle-facility/|archive-date=2021-03-29|dead-url=no}}</ref>。

2021年3月尾，香港[[衞生防護中心|衞生防護中心]]疫苗可預防疾病科學委員會主席劉宇隆向傳媒透露，香港特區政府打算訂購諾瓦瓦克斯COVID-19疫苗，作為[[香港2019冠狀病毒病疫苗接種計劃|香港2019冠狀病毒病疫苗接種計劃]]的第四款疫苗選項<ref>{{Cite web|title=專家指政府有意採購第 4 款疫苗 採重組蛋白技術 料為「美國 Novavax」或「成都威斯克」|url=https://www.thestandnews.com/society/專家指政府有意採購第-4-款疫苗-採重組蛋白技術-料為-美國-novavax-或-成都威斯克/|accessdate=2021-03-13|date=2021-03-13|work=立場新聞|archive-url=https://web.archive.org/web/20210314082912/https://www.thestandnews.com/society/%E5%B0%88%E5%AE%B6%E6%8C%87%E6%94%BF%E5%BA%9C%E6%9C%89%E6%84%8F%E6%8E%A1%E8%B3%BC%E7%AC%AC-4-%E6%AC%BE%E7%96%AB%E8%8B%97-%E6%8E%A1%E9%87%8D%E7%B5%84%E8%9B%8B%E7%99%BD%E6%8A%80%E8%A1%93-%E6%96%99%E7%82%BA-%E7%BE%8E%E5%9C%8B-novavax-%E6%88%96-%E6%88%90%E9%83%BD%E5%A8%81%E6%96%AF%E5%85%8B/|archive-date=2021-03-14|dead-url=no}}</ref>。然而，由於香港相關接種計劃的接種率偏低，導致已投入應用的疫苗出現過剩情況，目前政府暫時未有再討論訂購諾瓦瓦克斯COVID-19疫苗事宜。

2021年7月，諾瓦瓦克斯醫藥證實[[台灣|台灣]]已通過COVAX平台採購诺瓦瓦克斯2019冠状病毒病疫苗<ref name="台灣早透過COVAX訂購諾瓦瓦克斯">{{cite news |title=諾瓦瓦克斯證實︰台灣早透過COVAX訂購疫苗 |url=https://news.ltn.com.tw/news/life/paper/1458290 |accessdate=2021-07-08 |work=自由時報 |date=2021-07-03 |archive-date=2021-07-11 |archive-url=https://web.archive.org/web/20210711093948/https://news.ltn.com.tw/news/life/paper/1458290 |dead-url=no }}</ref>，[[中華民國衛生福利部|衛福部]]防疫指揮官[[陳時中|陳時中]]在7月2日表示除了通過COVAX採購，也已經與諾瓦瓦克斯醫藥談判直接採購疫苗<ref name="台灣談判直接採購諾瓦瓦克斯">{{cite news |title=不只從COVAX取得諾瓦瓦克斯疫苗 陳時中：正與原廠談判 |url=https://udn.com/news/story/122190/5574008 |accessdate=2021-07-08 |work=聯合報 |date=2021-07-02 |archive-date=2021-07-09 |archive-url=https://web.archive.org/web/20210709185026/https://udn.com/news/story/122190/5574008 |dead-url=no }}</ref>。

2021年8月4日，[[欧洲联盟委员会|欧盟委员会]]和[[诺瓦瓦克斯医药|Novavax]]宣布欧盟委员会批准一项1亿剂的预购协议，外加1亿剂作为购买选择。 一旦[[欧洲药品管理局|EMA]] 批准该疫苗，则从2021年第四季度开始供货<ref>{{Cite web|date=2021-08-04|title=Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine - Aug 4, 2021|url=https://ir.novavax.com/2021-08-04-Novavax-and-European-Commission-Finalize-Advance-Purchase-Agreement-for-up-to-200-million-doses-of-COVID-19-Vaccine?sf148464829=1|url-status=no|access-date=2021-08-04|website=novavax.com|language=en|archive-date=2021-08-09|archive-url=https://web.archive.org/web/20210809141219/https://ir.novavax.com/2021-08-04-Novavax-and-European-Commission-Finalize-Advance-Purchase-Agreement-for-up-to-200-million-doses-of-COVID-19-Vaccine?sf148464829=1}}</ref><ref>{{Cite web|date=2021-08-04|title=Coronavirus: Commission approves new contract for a potential COVID-19 vaccine with Novavax|url=https://ec.europa.eu/commission/presscorner/home/en|url-status=no|access-date=2021-08-04|website=European Commission|language=en|archive-date=2020-08-25|archive-url=https://web.archive.org/web/20200825095835/https://ec.europa.eu/commission/presscorner/home/en}}</ref>。

2021年11月1日，印尼藥監部門批准诺瓦瓦克斯疫苗在該國緊急使用<ref name="Indonesia">{{Cite news|last=Reuters|date=2021-11-01|title=Novavax COVID-19 vaccine receives first emergency use authorization|language=en|work=Reuters|url=https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-covid-19-vaccine-receives-emergency-use-authorization-indonesia-2021-11-01/|access-date=2021-11-01|archive-date=2021-12-24|archive-url=https://web.archive.org/web/20211224034919/https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-covid-19-vaccine-receives-emergency-use-authorization-indonesia-2021-11-01/|dead-url=no}}</ref>，為此疫苗在全球獲得的首個使用許可；16日後，菲律賓亦批准此疫苗在當地應用<ref>{{cite news |title=Philippines approves emergency use of Novavax's COVID-19 vaccine |url=https://www.reuters.com/business/healthcare-pharmaceuticals/philippines-approves-emergency-use-novavaxs-covid-19-vaccine-2021-11-17/ |access-date=2021-11-17 |publisher=Reuters |date=2021-11-17 |archive-date=2021-12-23 |archive-url=https://web.archive.org/web/20211223012200/https://www.reuters.com/business/healthcare-pharmaceuticals/philippines-approves-emergency-use-novavaxs-covid-19-vaccine-2021-11-17/ |dead-url=no }}</ref>
。

2022年3月24日，中華民國[[嚴重特殊傳染性肺炎中央流行疫情指揮中心|中央流行疫情指揮中心]]表示採購Novavax疫苗，總數逾200萬劑<ref>{{cite news |author1=蘇龍麒 |title=陳時中證實採購Novavax疫苗 逾200萬劑抵台時間待定 |url=https://www.cna.com.tw/news/ahel/202203245003.aspx |accessdate=2022-06-20 |agency=中央社 |date=2022-03-24}}</ref>。2022年6月18日，指揮中心表示預訂200萬劑Novavax疫苗有望7月陸續到貨<ref>{{cite news |author1=張茗喧 |title=幼兒莫德納估7月中下旬開打 Novavax最快7月到貨 |url=https://www.cna.com.tw/news/ahel/202206180107.aspx |accessdate=2022-06-20 |agency=中央社 |date=2022-06-18}}</ref>。第一批50.4萬劑疫苗於6月30日運抵臺灣<ref>{{cite news |author1=吳亮儀 |title=首批50.4萬劑Novavax疫苗抵台 檢驗封緘照片曝光 |url=https://news.ltn.com.tw/news/life/breakingnews/3977084 |accessdate=2022-06-30 |work=自由時報 |date=2022-06-30}}</ref>。

== 参考文献 ==
{{Reflist|35em}}

== 外部連結 ==
{{Scholia}}

== 参见 ==
{{Portal|2019冠状病毒病|病毒|药理学|医学|美国}}
*[[2019冠状病毒病疫苗|2019冠状病毒病疫苗]]
*[[亚单位疫苗|亚单位疫苗]]
*[[智克威得2019冠状病毒病疫苗|智克威得2019冠状病毒病疫苗]]
*[[高端新冠肺炎疫苗|高端新冠肺炎疫苗]]
*[[阿布达拉2019冠状病毒病疫苗|阿布达拉2019冠状病毒病疫苗]]
*[[主权二号2019冠状病毒病疫苗|主权二号2019冠状病毒病疫苗]]

{{-}}
{{COVID-19}}
{{Vaccines}}

[[Category:临床试验|Category:临床试验]]
[[Category:美国2019冠状病毒病疫苗|Category:美国2019冠状病毒病疫苗]]
[[Category:2021年面世的產品|Category:2021年面世的產品]]
[[Category:美國發明|Category:美國發明]]
[[Category:亚单位疫苗|Category:亚单位疫苗]]